Author: Ken Dropiewski

PhysIQ and U.S. Veteran’s Affairs Publish Breakthrough Study Predicting Heart Failure Hospitalization up to 10 days in Advance using AI

PhysIQ and the U.S. VA publish results of a clinical trial that demonstrates how artificial intelligence (AI) applied to continuous wearable sensor data may predict hospitalizations. When coupled with the high sensor wear compliance rates, the 7-10-day early warning timeframe suggests this approach has great promise to reduce hospitalization and […]

New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation

Pooled Analysis of Prospective Studies Presented during Late Breaking Trials Session at CRT 2020 KIRKLAND, Wash., Feb. 25, 2020 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of […]

BioStable Science & Engineering Announces Initial Closing of Series C Equity Round

Rex Health Ventures and Orlando Health Ventures lead strong syndicate of new and existing investors AUSTIN, Texas–(BUSINESS WIRE)–BioStable Science & Engineering, a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, announced today the initial closing of its Series C equity financing. Lead […]

BIOTRONIK’s Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results After Three Years

Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro’s Ability to Outperform Abbott’s Xience NATIONAL HARBOR, Md., Feb. 24, 2020 /PRNewswire/ — BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical […]

Anne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board

Former CEO of Freeline Therapeutics, Ltd. has outstanding international drug development, commercialization expertise, with focus on rare disease, gene therapy PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board […]

Endologix Announces Debt Restructuring Addressing 2020 Maturities

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the “Existing Notes”), pursuant to which these investors […]

Edwards Lifesciences’ Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients

IRVINE, Calif., Feb. 21, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced a new goal for its philanthropic initiative, Every Heartbeat Matters (EHM): to improve the lives of 2.5 million additional underserved structural heart and critical care patients by the end […]

Cerus Endovascular Successfully Completes Series B Financing and Receives U.S. FDA Approval for its First Microcatheter

Completion of Series B Financing Round Strengthens and Readies the Company for Commercialization of Two Products During the Second Quarter of 2020 FREMONT, Calif. and OXFORD, England, Feb. 21, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has now successfully completed its Series B financing having […]

BioSig Announces $10 Million Public Offering of Common Stock

Westport, CT, Feb. 21, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has agreed to […]